TOP 1703: Osimertinib for Patients with Stage 4 Non-Small Cell Lung Cancer - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
Adults who have confirmed non-small cell lung cancer with EGFR Mutations
What is Involved?
If you choose to join this study, you will:
-Take Osimbertinib (80mg) by mouth
- Have routine eye exams and EKGs
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects